Corvus Pharmaceuticals (CRVS) Q1 2025 earnings summary

Executive summary

• Phase I trial of soquelitinib in atopic dermatitis showed favorable safety and efficacy, with the 200 mg BID cohort demonstrating earlier and deeper responses than lower doses and placebo in moderate to severe cases.

• The company is advancing soquelitinib in multiple indications, including atopic dermatitis, peripheral T-cell lymphoma (PTCL), and ALPS, with a Phase 3 trial enrolling in relapsed PTCL and additional trials planned.

• Protocol amendments replaced a planned cohort with an extension cohort for longer treatment duration, aiming to inform Phase 2 design.

• Early exercise of 8.95 million warrants in May 2025 generated $31.3 million in proceeds, extending operational runway into Q4 2026.

• Soquelitinib received FDA Fast Track and Orphan Drug designations for relapsed/refractory PTCL.

Financial highlights

• Research and development expenses rose to $7.5 million in Q1 2025 from $4.1 million in Q1 2024, mainly due to higher clinical and manufacturing costs.

• Net income for Q1 2025 was $15.2 million, including a $25.1 million non-cash gain from warrant liability revaluation; Q1 2024 saw a net loss of $5.7 million.

• Cash, cash equivalents, and marketable securities totaled $44.2 million as of March 31, 2025, down from $52 million at year-end 2024, with an additional $31.3 million from warrant exercises in May 2025.

• Total operating expenses for Q1 2025 were $9.9 million.

• No product revenue generated; all income is non-operating or from financing activities.

Outlook and guidance

• Current cash, including warrant proceeds, is expected to fund operations into Q4 2026, covering ongoing and planned trials in atopic dermatitis, PTCL, ALPS, and a solid tumor study.

• Data from the extension cohort in atopic dermatitis is anticipated in Q4 2025, with Phase 2 trial initiation planned before year-end.

• Interim data from the Phase 3 lymphoma trial is expected in late 2026.

• Additional capital will be needed for full development and commercialization.